ReviewCurrent osteoporosis reports2011
FGF23 in skeletal modeling and remodeling.
Review in Current osteoporosis reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 49 citations in OpenAlex.
- Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease.PloS one · 2015Trial
- Can salivary phosphate levels be an early biomarker to monitor the evolvement of obesity?Contributions to nephrology · 2013Trial
- Degeneration and adaptive evolution of digits in ratite birds.Molecular biology and evolution · 2026Article
- DMP1-Mediated FAK Activation Contributes to P Utilization of Broiler Osteoblasts by Suppressing FGF23 Expression.Biology · 2026Article
- Overexpression and Purification of Mitogenic and Metabolic Fibroblast Growth Factors.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Distinct role of Klotho in long bone and craniofacial bone: skeletal development, repair and regeneration.PeerJ · 2024Review
- Pharmacological intervention of the FGF-PTH axis as a potential therapeutic for craniofacial ciliopathies.Disease models & mechanisms · 2022Article
- The Emerging Role of Cell Transdifferentiation in Skeletal Development and Diseases.International journal of molecular sciences · 2022Review
- Primary Osteocyte Supernatants Metabolomic Profiling of Two Transgenic Mice With Connexin43 Dominant Negative Mutants.Frontiers in endocrinology · 2021Article
- ScxBone · 2021Article
- Review
- Chondrogenesis Defines Future Skeletal Patterns Via Cell Transdifferentiation from Chondrocytes to Bone Cells.Current osteoporosis reports · 2020Review
- Article
- Correlation of Fgf23 and Balp with Bone Mineral Density in Hemodialysis Patients.Journal of medical biochemistry · 2019Article
- Fibroblast Growth Factor 2 and Its Receptors in Bone Biology and Disease.Journal of the Endocrine Society · 2018Review
- Pth4, an ancient parathyroid hormone lost in eutherian mammals, reveals a new brain-to-bone signaling pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Article
- Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by β-blocker treatment.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016Article
- Knockout of nuclear high molecular weight FGF2 isoforms in mice modulates bone and phosphate homeostasis.The Journal of biological chemistry · 2014Article
- Regulation of mineral metabolism by lithium.Pflugers Archiv : European journal of physiology · 2014Article
- Predictors of intact and C-terminal fibroblast growth factor 23 in Gambian children.Endocrine connections · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Fibroblast growth factor 23 (FGF23), a hormone primarily produced in bone cells, targets the kidney to accelerate phosphate excretion into the urine and suppresses vitamin D synthesis, thereby inducing a negative phosphate balance. Excessive serum FGF23 due to hereditary disorders such as hypophosphatemic rickets leads to phosphate wasting and impaired bone mineralization. In contrast, deficiencies in FGF23 are associated with hyperphosphatemia, elevated 1,25(OH)(2)D(3), ectopic ossification in soft tissues, and defects in skeletal mineralization. Recent studies of human genetic disorders and genetically engineered mice, as well as the in vitro approaches, have clarified some mysteries in FGF23 regulation and its potential roles in bone modeling and remodeling, which are summarized in this review article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.